- AuthorisedTherapeutic exploratory (Phase II)
An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.
This study is testing a new cell therapy called tolDC for people with progressive forms of Multiple Sclerosis (MS). It aims to see if tolDC can slow down how MS affects your body and if it's safe to use.
For: Multiple SclerosisBelgium · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis
This study is looking into a new treatment called 'tolDC' for multiple sclerosis (MS). Researchers want to see if it's safe and helps reduce new changes in the brain that are often seen in people with MS.
For: Multiple SclerosisSpain · Belgium